Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Vertex Pharmaceuticals Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1989-01-01

Employees: 5.4K

Market Cap: $123.9B

Website: http://www.vrtx.com

Clinical Trials

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Phase 3

Recruiting

Conditions: Diabetes Mellitus, Type 1
Severe Hypoglycemia
Impaired Hypoglycemic Awareness

Interventions: Biological: VX-880

First Posted Date: 2021-03-08

Last Posted Date: 2025-05-23

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 52

Registration Number: NCT04786262

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Baylor Scott and White Research Institute, Dallas, Texas, United States
🇺🇸
City of Hope, Duarte, California, United States

and more 49 locations

ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation

Conditions: Cystic Fibrosis

First Posted Date: 2021-01-08

Last Posted Date: 2021-07-15

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Registration Number: NCT04702360

A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: ELX/TEZ/IVA
Drug: IVA

First Posted Date: 2020-10-22

Last Posted Date: 2023-08-03

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 69

Registration Number: NCT04599465

Locations: 🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
🇦🇺
The Prince Charles Hospital, Chermside, Australia
🇦🇺
Alfred Hospital, Melbourne, Australia

and more 38 locations

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: ELX/TEZ/IVA
Drug: IVA

First Posted Date: 2020-09-11

Last Posted Date: 2024-05-08

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 120

Registration Number: NCT04545515

Locations: 🇦🇺
Telethon Kids Institute, Nedlands, Australia
🇦🇺
Queensland Children's Hospital, South Brisbane, Australia
🇦🇺
The Children's Hospital at Westmead, Westmead, Australia

and more 31 locations

Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: ELX/TEZ/IVA
Drug: IVA

First Posted Date: 2020-09-03

Last Posted Date: 2023-06-28

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 83

Registration Number: NCT04537793

Locations: 🇺🇸
Banner University of Arizona Medical Center, Tucson, Arizona, United States
🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Children's Hospital of Colorado, Aurora, Colorado, United States

and more 19 locations

Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

Phase 2

Completed

Conditions: Alpha1-Antitrypsin Deficiency

Interventions: Drug: Placebo
Drug: VX-864

First Posted Date: 2020-07-16

Last Posted Date: 2022-05-26

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 44

Registration Number: NCT04474197

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
University of California Davis Medical Center, Sacramento, California, United States

and more 27 locations

A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: ELX/TEZ/IVA
Drug: IVA

First Posted Date: 2020-04-27

Last Posted Date: 2023-07-28

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 172

Registration Number: NCT04362761

Locations: 🇦🇺
The Prince Charles Hospital, Chermside, Australia
🇦🇺
Institute for Respiratory Health, Nedlands, Australia
🇦🇺
Telethon Kids Institute, Perth Children's Hospital, Nedlands, Australia

and more 26 locations

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Other: Placebo (matched to ELX/TEZ/IVA)
Drug: ELX/TEZ/IVA
Other: Placebo (matched to IVA)
Drug: IVA

First Posted Date: 2020-04-20

Last Posted Date: 2022-07-26

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 121

Registration Number: NCT04353817

Locations: 🇦🇺
Telethon Kids Institute, Nedlands, Australia
🇦🇺
Queensland Children's Hospital, South Brisbane, Australia
🇦🇺
The Children's Hospital at Westmead, Westmead, Australia

and more 31 locations

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Phase 2

Completed

Conditions: Glomerulosclerosis, Focal Segmental

Interventions: Drug: VX-147

First Posted Date: 2020-04-09

Last Posted Date: 2023-07-10

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 16

Registration Number: NCT04340362

Locations: 🇺🇸
University of Alabama at Birmingham - The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸
California Institute of Renal Research, San Diego, California, United States
🇺🇸
The George Washington University Medical Faculty Associates - Kidney Disease & Hypertension, Washington, District of Columbia, United States

and more 41 locations

Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: LUM/IVA

First Posted Date: 2020-01-21

Last Posted Date: 2023-09-21

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 52

Registration Number: NCT04235140

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 20 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy